These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 11041059)

  • 1. Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening.
    Rhodes A; Jasani B; Balaton AJ; Barnes DM; Miller KD
    J Clin Pathol; 2000 Sep; 53(9):688-96. PubMed ID: 11041059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries.
    Rhodes A; Jasani B; Balaton AJ; Miller KD
    J Clin Pathol; 2000 Apr; 53(4):292-301. PubMed ID: 10823126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency and reliability of oestrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: results of the RCPA Quality Assurance Program.
    Francis GD; Dimech M; Giles L; Hopkins A
    J Clin Pathol; 2007 Nov; 60(11):1277-83. PubMed ID: 17259294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of threshold values for determining the size of the fraction of steroid hormone receptor-positive tumor cells in paraffin-embedded breast carcinomas.
    Leers MP; Hoop JG; van Beers M; van Rodijnen N; Pannebakker M; Nap M
    Cytometry B Clin Cytom; 2005 Mar; 64(1):43-52. PubMed ID: 15668953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems.
    Rhodes A; Jasani B; Barnes DM; Bobrow LG; Miller KD
    J Clin Pathol; 2000 Feb; 53(2):125-30. PubMed ID: 10767828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. External quality assessment (EQA) program for the immunohistochemical detection of ER, PR and Ki-67 in breast cancer: results of an interlaboratory reproducibility ring study in China.
    Pu T; Shui R; Shi J; Liang Z; Yang W; Bu H; Li Q; Zhang Z;
    BMC Cancer; 2019 Oct; 19(1):978. PubMed ID: 31640622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-palpable breast carcinomas: correlation of mammographically detected malignant-appearing microcalcifications and molecular prognostic factors.
    Karamouzis MV; Likaki-Karatza E; Ravazoula P; Badra FA; Koukouras D; Tzorakoleftherakis E; Papavassiliou AG; Kalofonos HP
    Int J Cancer; 2002 Nov; 102(1):86-90. PubMed ID: 12353238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.
    Nordenskjöld A; Fohlin H; Fornander T; Löfdahl B; Skoog L; Stål O
    Breast Cancer Res Treat; 2016 Nov; 160(2):313-322. PubMed ID: 27722840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative Assessment of Immunohistochemistry Laboratory Performance by Measuring Analytic Response Curves and Limits of Detection.
    Sompuram SR; Vani K; Schaedle AK; Balasubramanian A; Bogen SA
    Arch Pathol Lab Med; 2018 Jul; 142(7):851-862. PubMed ID: 29595317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
    Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
    Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen and progesterone hormone receptor status in breast carcinoma: comparison of immunocytochemistry and immunohistochemistry.
    Radhika K; Prayaga AK
    Indian J Cancer; 2010; 47(2):148-50. PubMed ID: 20448377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neural Analyses Validate and Emphasize the Role of Progesterone Receptor in Breast Cancer Progression and Prognosis.
    Caronongan A; Venturini B; Canuti D; Dlay S; Naguib RN; Sherbet GV
    Anticancer Res; 2016 Apr; 36(4):1909-15. PubMed ID: 27069179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical expression of hormone receptors and the histological characteristics of biochemically hormone receptor negative breast cancers.
    Nishimura R; Saeki T; Ohsumi S; Tani Y; Takashima S
    Breast Cancer; 2007; 14(1):100-4. PubMed ID: 17245003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer.
    Allegra JC; Lippman ME; Thompson EB; Simon R; Barlock A; Green L; Huff KK; Do HM; Aitken SC
    Cancer Res; 1979 May; 39(5):1447-54. PubMed ID: 427788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Routine assessment of hormonal receptor and her-2/neu status underscores the need for more therapeutic targets in Kenyan women with breast cancer.
    Nyagol J; Nyong'o A; Byakika B; Muchiri L; Cocco M; de Santi MM; Spina D; Bellan C; Lazzi S; Kostopoulos I; Luzi P; Leoncini L
    Anal Quant Cytol Histol; 2006 Apr; 28(2):97-103. PubMed ID: 16637512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast hormonal receptors test should be repeated on excisional biopsy after negative core needle biopsy.
    Khoury T; Zakharia Y; Tan W; Kulkarni S; Liu W; Zhang S; Wilding GE; Edge S
    Breast J; 2011; 17(2):180-6. PubMed ID: 21306471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunochemistry for oestrogen receptor, progesterone receptor and HER2 on cell blocks in primary breast carcinoma.
    Kumar SK; Gupta N; Rajwanshi A; Joshi K; Singh G
    Cytopathology; 2012 Jun; 23(3):181-6. PubMed ID: 21375607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between hormone receptor status and tumour size, grade and comedo necrosis in ductal carcinoma in situ.
    Barnes NL; Boland GP; Davenport A; Knox WF; Bundred NJ
    Br J Surg; 2005 Apr; 92(4):429-34. PubMed ID: 15736216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of enzyme immunoassay and immunohistochemical measurements of estrogen and progesterone receptors in breast cancer patients.
    Ferrero-Poüs M; Trassard M; Le Doussal V; Hacène K; Tubiana-Hulin M; Spyratos F
    Appl Immunohistochem Mol Morphol; 2001 Sep; 9(3):267-75. PubMed ID: 11556756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome.
    Francis G; Beadle G; Thomas S; Mengersen K; Stein S
    Pathology; 2006 Oct; 38(5):391-8. PubMed ID: 17008275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.